Pre‐existing CD95‐based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD‐L1 and TGFβ inhibition
Pre‐existing CD95‐based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD‐L1 and TGFβ inhibition
Kenneth Sik Kwan Chan, Chi‐Leung Chiang, Wei Dai, Jeffrey Yan Ho Lau et al.
Journal
Clinical and Translational Medicine
Topics
Immunotherapy and Immune Responses
article
Pre‐existing CD95‐based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD‐L1 and TGFβ inhibition
Kenneth Sik Kwan Chan, Chi‐Leung Chiang, Wei Dai, Jeffrey Yan Ho Lau, Tai‐Chung Lam, Ngar Woon Kam, Dora L.�W. Kwong, Cho Yiu Lau, Victor Lee Ho Fun
article en
Abstract
No abstract available for this paper.
Publication Tag
Clinical and Translational MedicineVol. 15(11)
Institutions
Chinese University of Hong Kong (HK), University of Hong Kong - Shenzhen Hospital (CN), University of Hong Kong (HK)